The Future of AI in Drug Discovery

Cyclica is focused on helping you navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica can offer novel insight and analysis into your drugs’ effects using our in-house, drug-centric and structure-based bioinformatics platform. By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a protein structure. We further augment our structural information with cognitive computing to drive our biophysical simulations.  Cyclica’s pre-clinical insights and in silico predictions improve current attrition rates of lead therapeutic compounds, improve patient outcomes with fewer side effects, and breathe life back into shelved therapeutics.

Naheed Kurji is President and CEO of Cyclica, where he leads the team in delivering the next step in cloud-based drug discovery. Naheed focuses on corporate and business growth strategies to ensure the company is set up for success. Naheed received his MBA from the University of Toronto, Rotman School of Management. Prior to joining Cyclica, Naheed worked as an Associate Director at Bank of Montreal in Calgary where he was integral in multiple cross-border sponsor coverage deals.